Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
← catalyst calendarNCT05502237 · readout ≤ 681 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →. With Arcus Biosciences, Inc..
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,021actual
Sites
186
Countries
Argentina, Austria, Belgium +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-12 | actual | When the study began enrolling |
| Primary completion | Jun 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer
Interventions
- Drug: Zimberelimab — also filed as GS-0122, AB122
- Drug: Domvanalimab — also filed as GS-0154, AB154
- Drug: Pembrolizumab — also filed as KEYTRUDA®
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Paclitaxel
- Drug: Nab-paclitaxel
- Drug: Pemetrexed
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS) in Participants With Positive Programmed Cell Death-Ligand 1 (PD-L1) Expression (≥1%Tumor Cells) and in all Randomized Participants.
measured Up to 68 months
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed